Amicus Therapeutics, Inc.

NasdaqGM:FOLD Stock Report

Market Cap: US$3.4b

Amicus Therapeutics Valuation

Is FOLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FOLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FOLD ($11.58) is trading below our estimate of fair value ($44.9)

Significantly Below Fair Value: FOLD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for FOLD?

Other financial metrics that can be useful for relative valuation.

FOLD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.9x
Enterprise Value/EBITDA-215.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does FOLD's PS Ratio compare to its peers?

The above table shows the PS ratio for FOLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.6x
ALKS Alkermes
2.8x-0.7%US$4.3b
PTCT PTC Therapeutics
3.5x1.5%US$3.3b
KYMR Kymera Therapeutics
34.3x25.2%US$3.1b
RARE Ultragenyx Pharmaceutical
9.9x30.9%US$4.9b
FOLD Amicus Therapeutics
7.5x20.3%US$3.4b

Price-To-Sales vs Peers: FOLD is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (12.6x).


Price to Earnings Ratio vs Industry

How does FOLD's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: FOLD is good value based on its Price-To-Sales Ratio (7.5x) compared to the US Biotechs industry average (12.7x).


Price to Sales Ratio vs Fair Ratio

What is FOLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FOLD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ratio7.7x

Price-To-Sales vs Fair Ratio: FOLD is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FOLD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.58
US$17.33
+49.7%
13.2%US$20.00US$13.00n/a12
Oct ’25US$10.66
US$17.25
+61.8%
14.8%US$20.00US$13.00n/a12
Sep ’25US$11.61
US$17.18
+48.0%
15.5%US$20.00US$13.00n/a11
Aug ’25US$10.20
US$17.36
+70.2%
15.8%US$21.00US$13.00n/a11
Jul ’25US$9.80
US$17.36
+77.2%
15.8%US$21.00US$13.00n/a11
Jun ’25US$9.80
US$17.36
+77.2%
15.8%US$21.00US$13.00n/a11
May ’25US$10.43
US$18.78
+80.0%
12.2%US$22.00US$14.00n/a9
Apr ’25US$11.75
US$19.00
+61.7%
9.9%US$22.00US$16.00n/a9
Mar ’25US$13.29
US$19.22
+44.6%
10.3%US$22.00US$16.00n/a9
Feb ’25US$12.67
US$19.56
+54.3%
8.4%US$22.00US$16.00n/a9
Jan ’25US$14.19
US$19.33
+36.2%
9.1%US$21.00US$15.00n/a9
Dec ’24US$11.22
US$18.10
+61.3%
16.1%US$21.00US$12.00n/a10
Nov ’24US$10.98
US$17.50
+59.4%
16.6%US$21.00US$12.00n/a10
Oct ’24US$12.16
US$17.60
+44.7%
15.9%US$21.00US$12.00US$10.6610
Sep ’24US$12.92
US$16.40
+26.9%
15.0%US$20.00US$12.00US$11.6110
Aug ’24US$13.41
US$15.90
+18.6%
14.7%US$20.00US$12.00US$10.2010
Jul ’24US$12.56
US$15.80
+25.8%
14.4%US$20.00US$12.00US$9.8010
Jun ’24US$11.39
US$15.80
+38.7%
14.4%US$20.00US$12.00US$9.8010
May ’24US$11.90
US$15.70
+31.9%
15.6%US$20.00US$11.00US$10.4310
Apr ’24US$11.09
US$15.82
+42.6%
15.0%US$20.00US$11.00US$11.7511
Mar ’24US$13.54
US$15.45
+14.1%
14.7%US$20.00US$11.00US$13.2911
Feb ’24US$13.16
US$15.36
+16.7%
16.0%US$20.00US$10.00US$12.6711
Jan ’24US$12.21
US$14.82
+21.4%
16.7%US$20.00US$10.00US$14.1911
Dec ’23US$12.28
US$14.82
+20.7%
16.7%US$20.00US$10.00US$11.2211
Nov ’23US$10.36
US$14.64
+41.3%
16.6%US$20.00US$10.00US$10.9811
Oct ’23US$10.44
US$14.45
+38.5%
17.3%US$20.00US$10.00US$12.1611

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies